Your browser doesn't support javascript.
loading
Probing the lithium-response pathway in hiPSCs implicates the phosphoregulatory set-point for a cytoskeletal modulator in bipolar pathogenesis.
Tobe, Brian T D; Crain, Andrew M; Winquist, Alicia M; Calabrese, Barbara; Makihara, Hiroko; Zhao, Wen-Ning; Lalonde, Jasmin; Nakamura, Haruko; Konopaske, Glenn; Sidor, Michelle; Pernia, Cameron D; Yamashita, Naoya; Wada, Moyuka; Inoue, Yuuka; Nakamura, Fumio; Sheridan, Steven D; Logan, Ryan W; Brandel, Michael; Wu, Dongmei; Hunsberger, Joshua; Dorsett, Laurel; Duerr, Cordulla; Basa, Ranor C B; McCarthy, Michael J; Udeshi, Namrata D; Mertins, Philipp; Carr, Steven A; Rouleau, Guy A; Mastrangelo, Lina; Li, Jianxue; Gutierrez, Gustavo J; Brill, Laurence M; Venizelos, Nikolaos; Chen, Guang; Nye, Jeffrey S; Manji, Husseini; Price, Jeffrey H; McClung, Colleen A; Akiskal, Hagop S; Alda, Martin; Chuang, De-Maw M; Coyle, Joseph T; Liu, Yang; Teng, Yang D; Ohshima, Toshio; Mikoshiba, Katsuhiko; Sidman, Richard L; Halpain, Shelley; Haggarty, Stephen J; Goshima, Yoshio.
Afiliação
  • Tobe BTD; Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA 92037.
  • Crain AM; Sanford Consortium for Regenerative Medicine, La Jolla, CA 92037.
  • Winquist AM; Department of Psychiatry, Veterans Administration Medical Center, La Jolla, CA 92037.
  • Calabrese B; Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA 92037.
  • Makihara H; Sanford Consortium for Regenerative Medicine, La Jolla, CA 92037.
  • Zhao WN; Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA 92037.
  • Lalonde J; Sanford Consortium for Regenerative Medicine, La Jolla, CA 92037.
  • Nakamura H; Sanford Consortium for Regenerative Medicine, La Jolla, CA 92037.
  • Konopaske G; Section of Neurobiology, Division of Biological Sciences, University of California, San Diego, La Jolla, CA 92037.
  • Sidor M; Department of Molecular Pharmacology & Neurobiology, Yokohama City University Graduate School of Medicine, Yokohama 236-0004, Japan.
  • Pernia CD; Chemical Neurobiology Laboratory, Center for Genomic Medicine, Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114.
  • Yamashita N; Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114.
  • Wada M; Chemical Neurobiology Laboratory, Center for Genomic Medicine, Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114.
  • Inoue Y; Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114.
  • Nakamura F; Department of Molecular Pharmacology & Neurobiology, Yokohama City University Graduate School of Medicine, Yokohama 236-0004, Japan.
  • Sheridan SD; Mailman Research Center, McLean Hospital, Belmont, MA 02478.
  • Logan RW; Department of Psychiatry, Harvard Medical School, Boston, MA 02115.
  • Brandel M; Department of Psychiatry, University of Connecticut School of Medicine, Farmington, CT 06030.
  • Wu D; Department of Psychiatry, University of Pittsburgh Medical Center, Pittsburgh, PA 15219.
  • Hunsberger J; Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA 92037.
  • Dorsett L; Sanford Consortium for Regenerative Medicine, La Jolla, CA 92037.
  • Duerr C; Department of Molecular Pharmacology & Neurobiology, Yokohama City University Graduate School of Medicine, Yokohama 236-0004, Japan.
  • Basa RCB; Department of Molecular Pharmacology & Neurobiology, Yokohama City University Graduate School of Medicine, Yokohama 236-0004, Japan.
  • McCarthy MJ; Department of Molecular Pharmacology & Neurobiology, Yokohama City University Graduate School of Medicine, Yokohama 236-0004, Japan.
  • Udeshi ND; Department of Molecular Pharmacology & Neurobiology, Yokohama City University Graduate School of Medicine, Yokohama 236-0004, Japan.
  • Mertins P; Chemical Neurobiology Laboratory, Center for Genomic Medicine, Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114.
  • Carr SA; Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114.
  • Rouleau GA; Department of Psychiatry, University of Pittsburgh Medical Center, Pittsburgh, PA 15219.
  • Mastrangelo L; Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA 92037.
  • Li J; Sanford Consortium for Regenerative Medicine, La Jolla, CA 92037.
  • Gutierrez GJ; Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA 92037.
  • Brill LM; Molecular Neurobiology Section, National Institute of Mental Health, Bethesda, MD 20892-1363.
  • Venizelos N; Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA 92037.
  • Chen G; Sanford Consortium for Regenerative Medicine, La Jolla, CA 92037.
  • Nye JS; Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA 92037.
  • Manji H; Sanford Consortium for Regenerative Medicine, La Jolla, CA 92037.
  • Price JH; Vala Sciences, Inc., San Diego, CA 92121.
  • McClung CA; Department of Psychiatry, Veterans Administration Medical Center, La Jolla, CA 92037.
  • Akiskal HS; Department of Psychiatry, University of California, San Diego, La Jolla, CA 92093-0737.
  • Alda M; Broad Institute of MIT and Harvard University, Cambridge, MA 02142.
  • Chuang DM; Broad Institute of MIT and Harvard University, Cambridge, MA 02142.
  • Coyle JT; Broad Institute of MIT and Harvard University, Cambridge, MA 02142.
  • Liu Y; Department of Psychiatry, Dalhousie University, Halifax, NS, Canada B3H 2E2.
  • Teng YD; Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA 92037.
  • Ohshima T; Sanford Consortium for Regenerative Medicine, La Jolla, CA 92037.
  • Mikoshiba K; Department of Neurology, Beth Israel-Deaconess Medical Center, Boston, MA 02215.
  • Sidman RL; Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA 92037.
  • Halpain S; Department of Biology, Vrije Universiteit Brussels, 1050 Brussels, Belgium.
  • Haggarty SJ; Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA 92037.
  • Goshima Y; Department of Cinical Medicine, Örebro University, Örebro SE-701 82, Sweden.
Proc Natl Acad Sci U S A ; 114(22): E4462-E4471, 2017 05 30.
Article em En | MEDLINE | ID: mdl-28500272
ABSTRACT
The molecular pathogenesis of bipolar disorder (BPD) is poorly understood. Using human-induced pluripotent stem cells (hiPSCs) to unravel such mechanisms in polygenic diseases is generally challenging. However, hiPSCs from BPD patients responsive to lithium offered unique opportunities to discern lithium's target and hence gain molecular insight into BPD. By profiling the proteomics of BDP-hiPSC-derived neurons, we found that lithium alters the phosphorylation state of collapsin response mediator protein-2 (CRMP2). Active nonphosphorylated CRMP2, which binds cytoskeleton, is present throughout the neuron; inactive phosphorylated CRMP2, which dissociates from cytoskeleton, exits dendritic spines. CRMP2 elimination yields aberrant dendritogenesis with diminished spine density and lost lithium responsiveness (LiR). The "set-point" for the ratio of pCRMP2CRMP2 is elevated uniquely in hiPSC-derived neurons from LiR BPD patients, but not with other psychiatric (including lithium-nonresponsive BPD) and neurological disorders. Lithium (and other pathway modulators) lowers pCRMP2, increasing spine area and density. Human BPD brains show similarly elevated ratios and diminished spine densities; lithium therapy normalizes the ratios and spines. Consistent with such "spine-opathies," human LiR BPD neurons with abnormal ratios evince abnormally steep slopes for calcium flux; lithium normalizes both. Behaviorally, transgenic mice that reproduce lithium's postulated site-of-action in dephosphorylating CRMP2 emulate LiR in BPD. These data suggest that the "lithium response pathway" in BPD governs CRMP2's phosphorylation, which regulates cytoskeletal organization, particularly in spines, modulating neural networks. Aberrations in the posttranslational regulation of this developmentally critical molecule may underlie LiR BPD pathogenesis. Instructively, examining the proteomic profile in hiPSCs of a functional agent-even one whose mechanism-of-action is unknown-might reveal otherwise inscrutable intracellular pathogenic pathways.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Transtorno Bipolar / Processamento de Proteína Pós-Traducional / Células-Tronco Pluripotentes Induzidas / Lítio / Modelos Biológicos Tipo de estudo: Etiology_studies / Prognostic_studies Limite: Animals / Humans Idioma: En Revista: Proc Natl Acad Sci U S A Ano de publicação: 2017 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Transtorno Bipolar / Processamento de Proteína Pós-Traducional / Células-Tronco Pluripotentes Induzidas / Lítio / Modelos Biológicos Tipo de estudo: Etiology_studies / Prognostic_studies Limite: Animals / Humans Idioma: En Revista: Proc Natl Acad Sci U S A Ano de publicação: 2017 Tipo de documento: Article